Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9620680 | 0.89 | ACHE (0.51) | ACHEABCC4ABCB11CHRM2ADRA2A | |
| SCHEMBL17043164 | 0.86 | ACHE (0.42) | ACHEABCC4ABCB11CHRM2ADRA2A | |
| SCHEMBL27029704 | 0.86 | HTR2A (0.43) | ACHEABCC4ABCB11CHRM2ADRA2A | |
| SCHEMBL30701777 | 0.86 | HTR2A (0.43) | ACHEABCC4ABCB11CHRM2ADRA2A | |
| SCHEMBL3083342 | 0.86 | HSD17B1 (0.46) | ACHEPDE4DBRD4HSD17B1ALDH1A1 | |
| SCHEMBL17043171 | 0.86 | BRD4 (0.41) | ACHEBRD4PTGS2HSD17B1PBRM1 | |
| SCHEMBL11811840 | 0.84 | BRD4 (0.46) | ACHEBRD4PTGS2MAOBHRH3 | |
| SCHEMBL19607444 | 0.84 | ACHE (0.42) | ACHEABCC4ABCB11CHRM2ADRA2A | |
| SCHEMBL9741669 | 0.82 | TUBB4A (0.38) | ACHEBRD4PTGS2HSD17B1KDM4E | |
| SCHEMBL3965311 | 0.81 | MAOB (0.38) | ACHESLC6A4BRD4PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| EP-2913324-B1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2017-12-20 | — | — | EP | disclosed |
| US-9637454-B2 | Fluorine substituted cyclic amine compounds and preparation methods, pharmaceutical compositions, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MADICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-05-02 | — | — | US | disclosed |
| US-20150284331-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-10-08 | — | — | US | disclosed |
| EP-2913324-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-09-02 | — | — | EP | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-20090137629-A1 | Sigma receptor binding agent containing indanone derivative | IIMURA YOICHI | 2009-05-28 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| CN-100396670-C | N-substituted 3-aminobenzene-pyrazoles as PDFG receptor inhibitors, pharmaceutical compositions and uses | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-25 | — | — | CN | disclosed |
| US-20050107432-A1 | Sigma receptor binder containing indanone derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1047674-B1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVES | EISAI CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1468684-A1 | SIGMA RECEPTOR BINDER CONTAINING INDANONE DERIVATIVE | Eisai Co., Ltd. (JP) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
| EP-1047674-A1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036405-A1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVE | EISAI CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | ACHE 4811/4885ABCC4 3464/4885ABCB11 3235/4885 |
| US-20090137629-A1 | Sigma receptor binding agent containing indanone derivative | SIGMAR1, TMEM97, OPRK1 | ACHE 608/4885ABCC4 1798/4885ABCB11 1172/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ACHE 3/4885ABCC4 2107/4885ABCB11 2838/4885 |
| US-20150284331-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ACHE, BCHE, CHRM3 | ACHE 1/4885ABCC4 672/4885ABCB11 169/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | ACHE 4778/4885ABCC4 4029/4885ABCB11 4364/4885 |
| US-20050107432-A1 | Sigma receptor binder containing indanone derivative | SIGMAR1, OPRK1, TMEM97 | ACHE 2667/4885ABCC4 375/4885ABCB11 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.